BINDING AGENT

Abstract: This invention relates to agents which bind to cell surface receptors; methods to manufacture said agents; therapeutic compositions comprising said agents; and screening methods to identify novel agents.

Description: BINDING AGENT FIELD OF THE INVENTION This invention relates to agents which bind to cell surface receptors; methods to manufacture said agents; therapeutic compositions comprising said agents; and screening methods to identify novel agents. BACKGROUND OF THE INVENTION Intercellular and/or intracellular signalling via receptor mediated activation of biochemical and/or molecular mechanisms is a fundamental process for regulating cellular and/or tissue homeostasis. Typically, ligands which interact with receptors to bring about a suitable biochemical response are known as agonists and those that prevent, or hinder, a biochemical response are known as antagonists. For example, and not by way of limitation, cell specific growth factors are ligands that act as agonists and bind receptors located at the cell surface. Activation of the receptors by ligand-specifϊc binding promotes cell proliferation via activation of intracellular signalling cascades that result in the expression of, amongst other things, cell-cycle specific genes, and the activation of quiescent cells to proliferate. Growth factors may also activate cellular differentiation. A large group of growth factors, referred to as cytokines, are involved in a number of diverse cellular functions. These include, by example and not by way of limitation, modulation of the immune system, regulation of energy metabolism and control of growth and development. Cytokines which are secreted by lymphocytes are termed lymphokmes (also Icnown as interleukins). Those secreted by monocytes and macrophages are termed monokines. Cytokines are also secreted by endocrine glands, (for example growth hormone (GH) by the pituitary gland), and adipose cells (for example leptin). Cytokines mediate their effects via receptors expressed at the cell surface on target cells. Receptors of the cytokine receptor family possess a single transmembrane domain and lack intrinsic enzyme activity (1). Upon the binding of a cytokine to a cognate receptor, either receptor homo- or hetero-dimerisation or oligomerisation occurs. The receptor complex is internalised and signalling occurs through the activation of associated signalling cascades that include the Jak/Stat and Mapk pathways. Internalisation is followed by a recycling step whereby the receptor molecule is regenerated for further use within the cell. The study of receptor/ligand interactions has been facilitated by the ability to define the structures of receptor molecules and their ligands. Several approaches, including X-ray crystallography and computer modelling, have greatly facilitated our understanding of the biology of ligand: receptor binding. An example of the above is described with respect to GH and its binding to the growth hormone receptor (GHR). This example is merely meant to be illustrative and not limiting and is an example of a cytokine which activates a signal transduction cascade by binding, dimerisation and internalisation ofthe receptor. 'ligand complex. It is known that a single molecule of growth hormone (GH) associates with two receptor molecules (3-6). This occurs through two unique receptor-binding sites on GH and a common binding pocket on the extracellular domain of two receptors. Site 1 on the GH molecule has a higher affinity than site 2, and receptor dimerization is thought to occur sequentially with one receptor binding to site 1 on GH followed by recruitment of a second receptor to site 2. The extracellular domain of the GHR exists as two linked domains each of approximately 100 amino acids (SD-100), the C-terminal SD-100 domain being closest to the cell surface and the N-terrriinal SD-100 domain being furthest away. It is a conformational change in these two domains that occurs on hormone binding with the formation of the trimeric complex GHR-GH-GHR (Fig 5). It has been proposed that ligand-driven receptor dimerization is the key event leading to signal activation (3), triggering phosphorylation cascades that include the Jak2/Stat5 pathway (7). Using confocal microscopy and Frequency Resonance Energy Transfer (FRET) it is known that there is very rapid internalisation of GHR after ligand binding and that internalisation and signalling are independent functions (16). Internalisation of the GHR-GH-GHR complex is followed by a recycling step whereby the receptor molecule is regenerated for further use within the cell. The importance of receptor dimerization in signal transduction is indicated by a number of experiments. High concentrations of GH, which favour the monomeric GH-GHR complex, inhibit the GH signal (8). Mutations in the inter-receptor dimerization domain inhibit signalling without influencing GH binding (10). The strongest evidence comes from work with a GH molecule mutated at site 2 to prevent receptor dimerisation. These GH mutants block GH-stimulated cell proliferation (8,11-14), the conformational change associated with receptor dimerization (15), and Jak-Stat signalling (16). US 5,849,535 describes a human growth hormone including a number of amino acid substitutions which disrupt Site 2 binding. The substitution of a different amino acid at G120 is one modification that disrupts Site 2 binding and the hGH variant acts as an hGH antagonist. The in vivo efficacy of hGH and hGH variants is determined, in part, by their affinity for the hGH receptor and rate of clearance from the circulation. The kidneys are relatively small organs which receive approximately 25% of cardiac output. The kidneys perform several important functions primarily related to the regulation of the composition and volume of body fluids. The kidneys filter about 100 litres of plasma every day and ofthe blood flow in and out of a kidney only approximately 1% becomes urine. Approximately 20% of the plasma that passes through the kidney gets filtered into the nephron. Filtration takes place in the glomerulus which is driven by the hydrostatic pressure ofthe blood. Water and small molecules are filtered whereas blood cells and large molecules, for example polypeptides, do not pass through the glomerular filter. Those, polypeptides with an effective molecular weight above 70 kDa are not cleared by glomerular filtration because they are simply too large to be filtered. Certain proteins of small molecular weight are filtered by the glomerulus and are found in the urine. For example, Growth Hormone (GH has a molecular weight of 22.1 kDa and the kidney is responsible for clearing up to 60-70% of GH in humans (Baumann, 1991; Haffner et al, 1994), and up to 67% in rat (Johnson & Maack, 1977). Other examples of relatively small molecular weight polypeptides which are filtered by the kidney include leptin, erythropoeitin, and IL-6. Syed et al (1997) constructed an anti-coagulant fusion protein which fused hirudin with albumin. This fusion protein showed extended plasma half life whilst maintaining a potent anti-thrombin (anti-coagulant) activity. This is likely to result from decrease in glomerular filtration by the kidneys. However a problem associated with this strategy is that hirudin is a foreign protein and which is known to provoke a strong immune response. The increase in molecular weight of the hirudin fusion protein increases the catabolic half-life from 0.7 hours to 4.6 days. A further method to increase the effective molecular weight of proteins and to produce a product which has reduced immunogenicity is to coat the protein in polyethylene glycol (PEG). The in-vivo half-life of GH has been increased by conjugating the proteins with poly ethylene glycol, which is termed "pegylation" (See Abuchowski et al, J.Biol Chem., 252:3582-3586 (1977). PEG is typically characterised as a non-immunogenic uncharged polymer with three water molecules per ethylene oxide monomer. PEG is believed to slow renal clearance by providing increased hydrodynamic volume in pegylated proteins (Maxfield et al., Polymer, 16:505-509 (1975)). US 5,849,535 also describes humanGH (hGH) variants which are conjugated to one or more polyols, such as poly(ethylene glycol) (PEG). An alternative to pegylation which provides a molecule which retains biological activity and is immune silent is herein disclosed. A chimeric protein comprising the extracelluar domain, or part thereof, of a receptor linked, via a variable flexible linker molecule to its cognate ligand to produce an agent with an apparent molecular weight greater than the native ligand. In the example provided, GH is fused to at least part of the growth hormone receptor (GHR) which gives an approximate molecular weight of 55kDa which when grycosylated increases the effective molecular weight to approximately 75kDa. This would be of sufficient size to prevent the chimera being filtered by the kidney and, importantly, the molecule retains biological activity. A long-acting form of growth hormone could be used in the treatment of both childhood and adult onset growth hormone deficiency. Growth hormone has well Icnown anabolic actions and a long-acting form of growth hormone could be used for the treatment of a number of conditions by virtue of its anabolic actions including promoting growth in Turner's syndrome, renal failure, osteoporosis and muscle wasting in catabolic patients. Bovine somatotropin is currently used to enhance milk production from cows. A long- acting form of growth hormone would be an effective treatment for increasing milk yield from cows (Peel et al. 1981). This strategy is applicable to other ligand-receptor combinations (eg. leptin, erythropoeitin and IL-6). For example, leptin is being trialed as a therapy for obesity (Mantzoros & Flier, 2000). A long-acting form of leptin could be used to treat obesity, insulin resistance, hyperlipidaemia and hypertension. Erythropoeitin is important in the generation of red cell mass. A long-acting form of erythropoeitin could be used to treat anaemia especially that associated with renal failure. Truncated GH receptors, which lack the cytoplasmic domain of the receptor, act as dominant negative inhibitors of GH signalling (9,19). The truncated receptor is expressed at a high level on the cell surface because it lacks the cytoplasmic domain essential for internalisation (16). In the presence of GH, the truncated receptor heterodimerises with the full length receptor and blocks signalling because it lacks the cytoplasmic domain. As the truncated receptor fails to internalise it acts as a dominant negative inhibitor preventing internalisation ofthe GH receptor complex. The disorders of acromegaly and gigantism result from an excess of growth hormone, usually due to pituitary tumours. A drug currently under trial is the pegylated GH antagonist B2036, designed using recently acquired knowledge of the molecular structure of the growth hormone receptor (GHR). Unfortunately, high levels of B2036 are required to antagonise GH action with drug levels over a 1000 times higher than endogenous GH levels (18). B2036, despite having a mutated site 2, binds to a receptor dimer, and is internalised in an identical fashion to GH. It does not however trigger the conformational change required for signalling. The high dose requirement of the antagonist relates to its internalisation and its differential binding to soluble and membrane bound receptor. The pegylated antagonist does not bind efficiently to membrane bound receptor although pegylation increases half-life and lowers immunogenicity. The non-pegylated antagonist is rapidly internalised and cleared. There is a need to provide an antagonist that is not internalised by the cell and that can be delivered in lower doses. This would prove a more effective and potent antagonist and provide a more effective and economical treatment. The leptin receptor (28) and erythropoietin (EPO) receptor (29,30) share considerable structural homology to the GHR and require a similar dimerisation process to trigger signalling. Leptin supresses appetite and leptin resistance is associated with obesity. A leptin receptor antagonist will provide a treatment for anorexia nervosa. EPO excess causes polycythaemia which may be secondary to hypoxia (chronic lung disease), or primary in the case of polycythaemia rubra vera (a disorder of excess red blood cells). An EPO antagonist will provide a therapy for polycythaemia. A further example of a receptor: ligand binding is provided by the IL-6 activation of its cognate receptor. The current model for IL-6 activation of its cognate receptor stipulates that IL-6 binds to either soluble or membrane bound IL-6 receptor (IL-6R). The IL-6 / IL-6R complex then recruits two molecules of gpl30 and the tetramer signals through the dimerisation of the two gpl30 molecules which possess cytoplasmic domains that associate with signalling molecules (Grotzinger et al, 1999). In nature IL-6 and the IL- 6R exist as separate molecules which possess high affinity binding sites for each other and the association with the signal transducing molecule gpl30 occurs through covalent linkage and the formation of disulfide bonds. We have been studying receptor trafficking and binding protein production for two members of the cytokine receptor family; GH and leptin (9,16,20,21). These two hormones play a fundamental role in determining body composition in adults. Both leptin and GH are important in regulating energy expenditure, appetite, and fat mass. The ability to manipulate the biological actions of leptin and GH will have important therapeutic outcomes for the treatment of both hormone excess and deficiency. Using confocal microscopy and Frequency Resonance Energy Transfer (FRET) we have shown that there is very rapid internalisation of GH receptor after ligand binding and that internalisation and signalling are independent functions (16). Our recent work shows that the GH antagonist, pegvisomant, despite having a mutated site 2, binds to a receptor dimer, is internalised in an identical fashion to GH, but does not trigger the conformational change required for signalling. We have demonstrated that the high dose requirement of the antagonist relates to its internalisation and its differential binding to soluble and membrane bound receptor. The pegylated antagonist does not bind efficiently to membrane bound receptor and the non-pegylated antagonist is rapidly internalised and cleared. We demonstrate that a truncated GHR, which lacks the cytoplasmic domain of the receptor, can act as a dominant negative antagonist of GH signalling, (Figure 5) (9,20). The truncated receptor is expressed at a high level on the cell surface as it lacks cytoplasmic domain essential for internalisation (16). The truncated receptor hetero dimerises with the full length receptor, blocks signalling as ij lacks the cytoplasmic domain, and acts as a dominant negative because it is present in excess on the cell surface and prevents internalisation ofthe GH receptor complex. There are two problems associated with using truncated receptors in the generation of antagonists to GH. A truncated receptor in the membrane would have to be generated from within the cell. The GHR is also proteolytically cleaved and in time the majority of the truncated receptor would be lost into the circulation. We link GH, through its C-terminus and a linker, to the N-terminus of the C-terminal SD-100 domain of the GHR. By varying the length of the linker we define a molecule that has the flexibility to allow binding of GH through site 1 to full length receptor at the cell surface. The C-terminal SD-100 domain of the receptor will then rotate in to complete the trimeric structure GHR-GH-GHRtr where GHRtr is the C-terminal SD-100 domain. This complex neither signals nor internalises, and effectively antagonises GH action. It has the additional advantages of low immunogenicity and low clearance as the majority of GH is cleared via the GHR (22). We also demonstrate that the leptin receptor produces a soluble binding protein (21) as do many cytokine receptors (2), and the predominant peripheral form of the leptin receptor is a truncated receptor similar to the truncated GHR (27,28). Our recent work has demonstrated that truncated leptin receptors can inhibit leptin signalling. The erythropoietin (EPO) receptor shares a very similar crystal structure to GHR and an EPO chimera with the C-terminal SD100 of the EPO receptor would function as an antagonist. STATEMENTS OF INVENTION According to the present invention there is provided a binding agent comprising a first part capable of binding a ligand binding domain of a receptor linked to a^second part comprising a receptor binding domain wherein said binding agent modulates the activity ofthe receptor. In one embodiment of the invention, the binding agent antagonises the activity of the receptor. In an alternative embodiment of the invention, the binding agent agonises the activity of the receptor. Preferably the first part comprises a cytokine or the binding domain of a cytokine. More preferably still the first part comprises a cytokine or the binding domain of a cytokine selected from the following: growth hormone; leptin; erythropoietin; prolactin; TNF, interleukins (IL), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11; the p35 subunit of IL-12, IL-13, IL-15; granulocyte colony stimulating factor (G-CSF); granulocyte macrophage colony stimulating factor (GM-CSF); ciliary neurotrophic factor (CNTF); cardiotrophin-1 (CT-1); leukemia inhibitory factor (LIF); oncostatin M (OSM); interferon, IFNα and IFNγ. Preferably the second part of the binding agent comprises at least part of the cognate receptor of he cytokine or a part of an associated receptor. Preferably the first part is GH. Preferably the second part is one extracellular domain of GHR. More preferably the second part is the C-terminal SD-100 domain of GHR. In an alternative embodiment the first part is IL-6 or a binding domain of IL-6 and the second part is a part ofgp 130. An embodiment of the invention exploits the high affinity of a cytokine for its receptor and the failure of truncated receptors to internalise to generate a specific receptor antagonist which is a chimera of the cytokine and its cognate receptor. The binding agent of the invention has the important advantage that binding of the cytokine to its receptor does not trigger internalisation of the receptor-cytokine complex. This means that dosage ofthe antagonist can be minimised. In one embodiment ofthe invention, the binding agent is a fusion protein. In an alternative embodiment of the invention, the first part is linked by a linker to the second part. The linker may be flexible. The linker could be at any residue within the extracellular domain of the receptor which would allow growth hormone to flexibly bind with the free receptor at the cell surface. Where the first part is GH and the second part is one extracellular domain of GHR, the linkage may be made between any peptide residue in the GH and GHR. Preferably the linkage is made between a residue close to the C-terminus of the GH molecule and a residue close to the N-terminus of the GHR. More preferably the linkage is made between a residue close to the C-terminus ofthe GH molecule and a residue close to the N-terminal of the N-terminal of the C-terminal SD-100. More preferably the linkage is made at any of residues 126-128 of the N-terminus of the C-terminal SD-100 of the GHR. In one embodiment ofthe invention, the linkage is made at residue 127 ofthe N- terminus ofthe C-terminal SD-100. Preferably the linker is a peptide. It will be apparent to one skilled in the art that alternative linkers can be used to link first and second parts. By way of example and by no means of limitation, suitable linkers might be a nucleic acid (eg oligonucleotide); a peptide nucleic acid; a chemical crosslinker (eg polyoxyethlene). The crystal structure of the GHR-GH-GHR complex reveals that the distance between the C-terminus of GH (residue 191) and N-terminus of the C-terminus SD-100 (residue 126-128) is 10 A. This provides invaluable information with respect to linker design. Preferably the linlcer is a polypeptide which comprises 5 to 30 amino acid residues. More preferably the linlcer comprises 10 to 20 amino acid residues. More preferably the linker comprises at least one copy ofthe peptide: Gly Gly Gly Gly Ser (hereinafter referred to as "Gly4Ser"). In one embodiment ofthe invention the linlcer is 10 amino acids in length and comprises two copies of the Gly4Ser linker. In an alternative embodiment of the invention, the linlcer is 15 amino acids in length and comprises three copies of the Gly4Ser linlcer. In yet an alternative embodiment, the linker is 20 amino acids in length and comprises four copies ofthe Gly4Ser linlcer. According to a further aspect ofthe invention there is provided a nucleic acid molecule comprising a nucleic acid sequence which encodes a binding agent according to the invention selected from the group consisting of: i) the group comprising Figs 4, 5, 8, 9 and 21; ii) nucleic acids which hybridise to the sequences of (i) above and which have receptor modulating activity; and iii) nucleic acid sequences which are degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above. In a preferred embodiment of the invention said nucleic acid hybridises under stringent hybridisation conditions to the sequences represented in Figs 4,5,8,9, or 21. Stringent hybridisation/washing conditions are well known in the art. For example, nucleic acid hybrids that are stable after washing in O.lx SSC,0.1%> SDS at 60°C. It is well Icnown in the art that optimal hybridisation conditions can be calculated if the sequence of the nucleic acid is known. For example, hybridisation conditions can be determined by the GC content of the nucleic acid subject to hybridisation. Please see Sambrook et al (1989) Molecular Cloning; A Laboratory Approach. A common formula for calculating the stringency conditions required to achieve hybridisation between nucleic acid molecules of a specified homology is: T m = 81.5° C + 16.6 Log [Na + ] + 0.41[ % G + C] -0.63 (%formamide). Typically, hybridisation conditions uses 4 - 6 x SSPE (20x SSPE contains 175.3g NaCl, 88.2g NaH 2 PO 4 H 2 O and 7.4g EDTA dissolved to 1 litre and the pH adjusted to 7.4); 5- lOx Denhardts solution (50x Denhardts solution contains 5g Ficoll (type 400, Pharmacia), 5g polyvinylpyrrolidone abd 5g bovine serum albumen/500ml; lOOμg- l.Omg/ml sonicated salmon/herring DNA; 0.1-1.0%) sodium dodecyl sulphate; optionally 40-60% deionised formamide. Hybridisation temperature will vary depending on the GC content ofthe nucleic acid target sequence but will typically be between 42°- 65° C. According to a further aspect of the invention there is provided a polypeptide which is encoded by a nucleic acid molecule according to the invention. In a preferred embodiment of the invention the polypeptide so encoded is modified by deletion, addition or substitution of at least one amino acid residue. Ideally said modification enhances the antagonistic or agonistic effects of said polypeptide with respect to the inhibition or activation of receptor mediated cell signalling. Alternatively, or preferably, said modification includes the use of modified amino acids in the production of recombinant or synthetic forms of polypeptides. It will be apparent to one skilled in the art that modified amino acids include, by way of example and not by way of limitation, 4-hydroxyproline, 5-hydroxylysine, N 6 - acetyllysine, N 6 -methyIlysine, N δ ,N δ -dimethyllysine, N 6 ,N 6 ,N 6 -trimethyllysine, cyclohexyalanine. D-amino acids, ornithine. The incorporation of modified amino acids may confer advantageous properties on polypeptides comprising Fig 21. For example, the incorporation of modified amino acids may increase the affinity of the polypeptide for its binding site, or the modified amino acids may confer increased in vivo stability on the polypeptide thus allowing a decrease in the effective amount of therapeutic polypeptide administered to a patient. According to a yet further aspect of the invention there is provided a vector including a DNA molecule encoding a binding agent according to any preceding aspect or embodiment ofthe invention. In a preferred embodiment of the invention said vector is provided with means to recombinantly manufacture the binding agent ofthe invention. In a preferred embodiment of the invention said vector is an expression vector adapted for prokaryotic gene expression. Prokaryotic expression systems are well Icnown in the art and comprise vectors adapted for high level constitutive and inducible expression. Inducible expression systems are particularly advantageous if the recombinant polypeptide is toxic to the bacterial cell. Induction of expression is tightly regulated by promoters responsive to various inducers (eg IPTG inducible). Bacterial cells can be grown to stationary phase before induction thereby reducing harmful effects of toxic polypeptides. Additionally it is also well known in the art that certain polypeptides are difficult to manufacture recombinantly due, for example, to protein instability or problems of aggregation. It is well known that genetically modified bacterial strains are available which are mutated in genes (eg bacterial proteases) which facilitate the production of native and recombinant bacterial polypeptides. In a further preferred embodiment of the invention said vector is an expression vector adapted for eukaryotic gene expression. Typically said adaptation includes, by example and not by way of limitation, the provision of transcription control sequences (promoter sequences) which mediate cell/tissue specific expression. These promoter sequences may be cell/tissue specific, inducible or constitutive. Promoter is an ait recognised term and, for the sake of clarity, includes the following features which are provided by example only, and not by way of limitation. Enhancer elements are cis acting nucleic acid sequences often found 5' to the transcription initiation site of a gene (enhancers can also be found 3' to a gene sequence or even located in intronic sequences and are therefore position independent). Enhancers function to increase the rate of transcription of the gene to which the enhancer is linked. Enhancer activity is responsive to trans acting transcription factors (polypeptides) which have been shown to bind specifically to enhancer elements. The binding/activity of transcription factors (please see Eukaryotic Transcription Factors, by David S Latchman, Academic Press Ltd, San Diego) is responsive to a number of environmental cues which include, by example and not by way of limitation, intermediary metabolites (eg glucose, lipids), environmental effectors (eg light, heat). Promoter elements also include so called TATA box and RNA polymerase initiation selection (RIS) sequences which function to select a site of transcription initiation. These sequences also bind polypeptides which function, inter alia, to facilitate transcription initiation selection by RNA polymerase. Adaptations also include the provision of selectable markers and autonomous replication sequences which both facilitate the maintenance of said vector in either the eukaryotic cell or prokaryotic host. Vectors which are maintained autonomously are referred to as episomal vectors. Adaptations which facilitate the expression of vector encoded genes include the provision of transcription termination/polyadenylation sequences. This also includes the provision of internal ribosome entry sites (IRES) which function to maximise expression of vector encoded genes arranged in bicistronic or multi-cistronic expression cassettes. These adaptations are well Icnown in the art. There is a significant amount of published literature with respect to expression vector construction and recombinant DNA techniques in general. Please see, Sambrook et al (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory, Cold Spring Harbour, NY and references therein; Marston, F (1987) DNA Cloning Techniques: A Practical Approach Vol III IRL Press, Oxford UK; DNA Cloning: F M Ausubel et al, Current Protocols in Molecular Biology, John Wiley & Sons, Inc.(1994). In yet a further aspect of the invention there is provided a method to prepare a binding agent polypeptide according to the invention comprising: (i) growing a cell transformed or transfected with a vector or nucleic acid of the present invention in conditions conducive to the manufacture of said polypeptide; and (ii) purifying said polypeptide from said cell, or its growth environment. In a preferred method of the invention said vector encodes, and thus said recombinant polypeptide is provided with, a secretion signal to facilitate purification of said binding agent polypeptide. In yet a further aspect of the invention there is provided a cell transformed/transfected with the vector or nucleic acid according to the invention. Preferably said cell eukaryotic and is selected from: fungal; insect (eg Spodoptera frugiperda); amphibian; plant; mammalian. More preferably said cell is prokaryotic and is an E. coli cell. Preferably the binding agent of the present invention is used for the manufacture of a medicament for use in the treatment of acromegaly; gigantism; growth hormone deficiency, Turners syndrome; renal failure; osteoporosis, diabetes mellitus, cancer; obesity; insulin resistance; hyperlipidaemia; hypertension (leptin chimera); anaemia; autoimmune and infectious disease; inflammatory disorders including rheumatoid arthritis. According to a further aspect of the invention there is provided a pharmaceutical composition comprising the binding agent according to the mvention. Preferably said pharmaceutical composition includes a carrier, excipient and/or a diluent. The invention also provides for a method of treating a human or animal subject comprising administering an effective amount of the pharmaceutical composition/medicament to said subject. It will be apparent to one skilled in the art that the compositions/medicaments can be provided in the form of an oral or nasal spray, an aerosol, suspension, emulsion, and/or eye drop fluid. Alternatively the medicament may be provided in tablet form. Alternative delivery means include inhalers or nebulisers. Alternatively or preferably the medicament can be delivered by direct injection. It is also envisioned that the compositions/medicaments be delivered intravenously, intramuscularly, subcutaneously or topically. Further still, the compositions/medicaments may be taken orally or rectally. The invention also provides a method of reduced renal clearance of a molecule comprising forming a binding agent according to any embodiment ofthe invention An embodiment of the invention will now be described by example only and with reference to the following figures wherein; Figure 1 represents a schematic diagram of (a) pTrcHis-TOPO and its derivatives; (b) pTrcHis-TOPO/GHstop;(c)pTrcHis-TOPO/Ghstop/GHR;(d)pTrcFIis- TOPO/GH/link/GHR; (e) pTrcHis-TOPO/GH/linlc/flecGHRstop; f) pJONEXGHstop; pJONEXGHstoplink GHR; Figure 2 represents the sequence of the cDNA of the 588bp PCR amplified GH fragment;(The 3'- Notl site and two stop codons are shown in bold and italics respectively) Figure 3 represents the sequence of the cDNA of the 390bp PCR amplified GHR SD 100 fragment (The 5' EcoRI and 3' Hindlll restriction sites are shown in bold and the 3' stop codons are shown in italics); Figure 4 represents the nucleic acid sequence of the full length GHstopGHR SD100 construct; Figure 5 represents the nucleic acid sequence of the full length GHlinkGHR construct (Notl, EcoRI and Hindlll restriction sites are shown in bold and the two 3' stop codons are shown in italics); Figure 6: represents the protein sequence of full length GHlinkGHR (340 amino acids); Figure 7 represents the nucleic acid sequence of the 762bp PCR amplified full length extracellular domain of GHR (GHRflec) (the 5' EcoRI and Hindlll sites are shown in bold and the two 3' stop codons are shown in italics); Figure 8: represents the full length nucleic acid sequence of the GHlinkGHRfiec construct (the Notl, EcoRI and Hindlll site are shown in bold and the two 3' stop codons are shown in italics); Figure 9: represents the nucleic acid sequence of the 1157bp PCR fragment,GHlinlcGHR generated by oligonucleotides TrcRBSsacF and GHRA835H, (the Sad, Notl, EcoRI and Hindlll sites are shown in bold, the new ribosome binding site is shown in bold and underlined and the start/stop codons are shown in italics); Figure 10: represents the nucleic acid sequence of the 740bp PCR fragment, GHstop generated by nucleotides pTrcRBSsacI and TrcHindrev, (The Sad, Notl, EcoRI and Hindlll sites are shown in bold, the new ribosome binding site is shown in bold and underlined and the start/stop codons are shown in italics); Figui'e 11: represents the complete amino acid sequence of the GH/GHR receptor chimera (GH residues 1-191/ linlcer /GHR residues 127-246). Figure 12A represents the full length nucleic acid sequence of IL-6; Figure 12B represents the amino acid sequence of IL-6; Figure 12 represents the full length nucleic acid sequence of gpl30; Figure 13 represents the amino acid sequence ofthe IL-6 /gpl30 fusion polypeptide; Figure 14 represents the nucleic acid sequence of the gp 130 domain 1 deletion (616- 2112bp); Figure 15 represents the nucleic acid sequence of gpl30 domain 922-2112bp; Figure 16 represents a western blot of induced proteins expressed by E. coli transformed with various vectors; Figure 17 (a) is a graphical representation of reporter gene assays for Ghstop and GH link GHR; and (b) quantification ofthe data represented in (a); and Figure 18 is a schematic representation of GF GHR interaction and GH:GHR chimera interaction with GHR. Figure 19 represents the in vitro agonist activity ofthe GH/GHR chimera. Figure 20 shows the results of a bioassay comparing the induction of a Stat5 reporter (luciferase activity) by growth hormone (GH), a negative control (XL blue) and partially purified antagonist (Chimera 1 A2) Figure 21 represents the nucleotide sequence ofthe Chi 1A2 chimera. Figure 22 represents the protein sequence of Chi 1A2 chimera (311 amino acids). MATERIALS AND METHODS Table 3 explains the nomenclature used to define the protein constructs. Generation of GH.GHR Fusion Protein Six constructs are cloned (including 3 different lengths of linlcer with or without the C241 ofthe GHR) into a C-terminal poly-His expression vector. Human GH is amplified using high fidelity proof reading Pfu with convenient restriction sites to clone into the vector. The C-terminus SD-100 GHR is similarly amplified and the linlcer constructed in the primer with convenient restriction sites to clone into the C-terminus of GH. The constructs are then fully sequenced. From the crystal structure of the GHR-GH-GHR complex, the distance between the C- terminus of GH (residue 191) and N-terminus of the C-Terminus SD-100 GHR (residue 126-128) is 10 A. Linkers between 10-20 residues are designed and three constructs made with linkers of either 10, 15 or 20 residues comprising of 2, 3 or 4 copies of the basic Gly 4 Ser linker. Protein Purification The constructs are expressed in E. coli (JM109) and the protein purified on Invitrogen Xpress System Nickel columns with a secondary purification step by ion exchange chromatography. Lipopolysaccharide should not interfere with the bioassay as this requires a relatively short incubation in the cell culture system. If required the chimera antagonist is further purified using polymyxin B columns (Pierce). Screening of Antagonist Activity An established bioassay is used to screen for antagonist activity (9). A permanent cell line expressing the full length GHR is transiently transfected with a luciferase reporter that binds activated Stat5 (9). Twenty-four hours later the cells are stimulated with GH for 6 hours with or without antagonist. The cells are then lysed and luciferase activity measured (9). Screening of Agonist Activity A permanent cell line expressing the full length GHR is transiently transfected with a luciferase reporter that binds activated Stat5 (9). Twenty-four hours later the cells are stimulated with or without the GH/GHR chimera for 6 hours. The cells are then lysed and luciferase activity measured (9). PCR OF PITUITARY GH FROM PITUITARY cDNA TO GENERATE GHstop Full-length human growth hormone was amplified from human pituitary cDNA using the Boehringer Expand High Fidelity PCR System. Each reaction consisted of: Primers GHSl-23 (forward) and GHA573not (reverse) lOμM each, 200μM dNTPs, 5μl Expand buffer plus magnesium chloride (1.5mM), and 0.6μl High fidelity enzyme mix in a total volume of 50μl. Samples were as follows 1. Pituitary cDNA using GHS 1 -23 and GHA573not primers 2. Pituitary cDNA using actin specific primers 3. Control cDNA for actin 4. Water control. PCR reaction master mix 1. Master Mix 2 (per reaction) 10 x Expand High Fidelity buffer (plus magnesium) (5μl) Sterile distilled water (19.4μl) Expand High Fidelity Expand polymerase (0.6μl) Added 25μl Master Mix 2 to Master mix 1 and overlaid with mineral oil. PCR was carried out to the following method: 94°C: 2 minutes, 94°C: 30sec / 54°C: 1 minute / 72°C: 1 minute, for 30 cycles 72°C: lOmin. The 5 '-nucleotide (GHSl-23) has sequence homology to the 5' end of the growth hormone gene and the 3 '-nucleotide (GHA573not) contains a Not I site together with two stop codons. The PCR reaction produced a band of 588bp (see Figure 2) containing full-length human growth hormone. The fragment was then purified using the QIAquick PCR purification kit (Qiagen) and subsequently TOPO cloned into the pTrcHis-TOPO vector (Invitrogen, see Figure 1). Ligations were transformed in to E. coli TOPO one shot cells (Invitrogen) by the calcium chloride method. Plasmid mini preparations were produced from positive transformants and screened by restriction digest using PstllEcoRl. Clones with the correct insert size were then sequenced using vector specific primers supplied by invitrogen that bind 5' and 3' to the insert region (Xpress forward primer and pTrcHis reverse primer, see Table 1). This construct was named pTrcHis GHstop and was used as the template for subsequent cloning reactions. Forward primer for Growth hormone primer "GHSl-23": 5'ttcccaaccattcccttatccag 3' Reverse primer GHA573not 5 'ttatcagcggccgccgaagccacagctgccctccac 3 ' PCR of GHR C-terminal SD100 domain from human liver cDNA The GHR C-terminal SD100 domain (Figure 3) was amplified from human liver cDNA using the same PCR method as previously described, but using primers GHRS476 (forward) and GHRA835H (reverse), see table 1. The 5 '-nucleotide contains an EcoRI site whilst the 3 '-nucleotide contains two stop codons and a Hindlll site. The PCR reaction was carried out and cleaned up as described previously. Samples were as follows: 1. liver cDNA using GHR476 and GHRA835H 2. liver cDNA using actin specific primers 3. Control cDNA 4. Water control. PCR reaction: Master Mix 1 Master Mix 2 (per reaction) 10 x Expand High Fidelity buffer (plus MgC12) (5μl) Sterile distilled water (19.4μl) High Fidelity Expand polymerase (0.6μl) Added 25 μl Master Mix 2 to Master mix 1 and overlaid with mineral oil. Both vector, pTrcHisGHstop, and PCR product were subjected to a double digest using EcoRI and Hindlll restriction enzymes (Promega). The PCR product was cleaned up using QIAquick PCR purification kit and the digested pTrcHisGHstop vector was separated by agarose gel electrophoresis and purified using the QIAquick gel extraction kit. The digested PCR fragment containing the C-terminal SD100 domain of GHR was then ligated to the above digested vector and transformed in to TOPO one shot cells (invitrogen) by the calcium chloride method. Ligations were transformed in to E. coli TOPO one shot cells (Invitrogen). Plasmid mini preparations were produced from positive transformants and screened by restriction digest using BamHI/EcoRI (Promega) and by PCR screening using GHSl-23 and GHRA835H primers. Clones with the correct insert size were then sequenced using pTrcHis reverse and GHseqF primers (see Table 1). This vector was called pTrcHisGHstopGHR and was used as the vehicle for the insertion of linlcer regions of varying lengths between GH and GHR in to the Notl/ ΕcoRI sites. Figure 4 shows the full insert sequence for pTrcHisGHstopGHR. This construct allows the insertion of a linker molecule in to the Notl /ΕcoRI sites between Ghstop and GHlinlcGHR. Insertion of linker regions The initial linker was constructed composed of a 4x repeating sequence of four glycine residues and one serine residue (20 residues in total) by annealing oligonucleotides G4S4 (forward) and G4COM4 (reverse) see Table 1. The 5 '-nucleotide contains a Notl site and the 3 '-nucleotide contains an EcoRI site. The vector pTrcFIisGHstopGHR, was double digested with Νotl and Hindlll restriction enzymes and cleaned up using the QIAquick clean up kit (Qiagen). "G4S4" 5 ' ggccgcggtggcggaggtagtggtggcggaggtagcggtggcggaggttctggtggcggaggttccg 3 ' "G4COMS4" 5 ' aattcggaacctccgccaccagaacctccgccaccgctacctccgccaccactacctccgccaccgc 3 ' Preparation of linker insert; Oligonucleotides G4S4 and G4COMS4 were resuspended in annealing buffer [lOmM Tris-HCl, pH 7.5, 50mM NaCl, ImM ΕDTA] to a final concentration O.lpmol/μl. An equal volume of each oligonucleotide was then mixed and heated to 95 °C for 2 minutes and then allowed to cool over a lhour period. The oligonucleotide duplexes were then ligated to the Νotl /ΕcoRI double digested vector pTrcHisGHstopGHR and transformed in to TOPO one shot cells (Invitrogen) by the calcium chloride method. Plasmid mini preparations were produced from positive transformants and screened by restriction digest using Νotl/EcoRI and by PCR screening using GHSl-23 and GHRA835H primers. Clones with the correct insert size were then sequenced using pTrcHis reverse primer and GHseqF (see Table 1). This vector was called pTrcHisGHlinlcGHR (See figure 1). The ligation process removes the 3 ' stop codons within the GHstop region thus allowing transcription ofthe full length GHlinkGHR. The same strategy was employed in order to clone in the full length extracellular domain of GHR incorporating SD100 N and C-terminal domains. Construction of full length extracellular domain of GHR (GHRflec) The full length extracellular domain of GHR (SD100 N and C-terminal) was amplified using primers GHRSIECOR and GHRA835H (see Table 1) following the same PCR protocol as described earlier for the generation of GHstop. The 5 '-nucleotide (GHRSIECOR) contains an EcoRI site and the 3 '-nucleotide contains a Hindlll site. The PCR reaction produced a band of 762bp (see Figure 7) containing full length extracellular GHR and purified using Qiaquick PCR clean up kit (Qiagen). Both vector, pTrcHisGHlinlcGHR and PCR product were subjected to a double restriction digest using EcoRI and Hindlll restriction enzymes. The PCR product was cleaned up using QIAquick PCR clean up kits and the digested vector was separated by agarose gel electrophoresis and subsequently purified using the QIAquick gel extraction kit. Both vector, pTrcHisGHlinlcGHR, and PCR product were double digested with EcoRI and Hindlll, and cleaned up using QIAquick clean up kits (Qiagen). The digested PCR fragment was then ligated in to the digested pTrcHisGHlinlcGHR vector and transformed in to TOPO one shot cells (Invitrogen) by the calcium chloride method. Positive transformants were screened by restriction digest using EcoRI and Hindlll and by PCR using primers GHRSIECOR and GHRA835H. Clones with the correct sized insert were sequenced using GHseqF and the vector specific primer pTrcHis reverse. The new construct was called pTrcHisGHlinkGHRflec. This can then be used as a template for any future linker inserts. Cloning GHstop and GHlinkGHR into p JONEX4 pJONEX4 vector (See Figurel) was constructed in order to express inducible proteins that were potentially deleterious to the cell by placing them under the control of a strong repressor of transcription (cI857) and a heat inducible promoter (PLλ). The construction of pJONEX4 has been described elsewhere (Jon R. Sayers and Fritz Eckstein; Nucleic Acid Research, volumel9, Nol5, p4127-4132, 1991). The PLλ promoter region was cloned into pUC19 in the EcoRI site and engineered so that only one EcoRI site remained downstream of the promoter to produce pJONEX4. Genes wishing to be transcribed can be inserted into the Sacl/Hindlll region downstream of the PLλ promoter. This vector can be used to transform bacteria which specify a temperature sensitive lambda repressor (cI857), thus at low temperatures, below 30°C, transcription read through is prevented by the presence of the repressor protein. However, at higher temperatures (42 °C) induction of protein expression proceeds. The main aim was to construct primers in order to PCR up the full length GHstop and GHlinkGHR from their parent vector pTrcHis-TOPO and subclone these fragments into the SacI/FIindlll sites in pJONEX4. 5 '-nucleotide, TrcRBSsacF contains an engineered Sad restriction site, a new ribosome binding site and the ATG start codon present in the pTrcHis-TOPO vector. Two 3'- nucleotides will be used to PCR GHstop and GHlinkGHR respectively from their parent . vectors, pTrcHis. The 3 '-nucleotide, TrcHindrev, contains a HindlJJ site and will be used to PCR the full length GHstop gene. The other nucleotide, GHRA835H has already been described, and will be used to PCR up GHlinkGHR (see Table 1). TrcRBSSacIf: 5' gggaaa gagctc aaggagaaaataaa atg gggggttctcatcatcat 3 ' Sad RBS START pTrc vector TrcHindlllrev: 5 'gccaagcttcgaattgaattcg 3' PCR Method 96°C 2mins 94 ° C 30sec/54°C lmin/72°C lmin, for 30 cycles 72°C10mins PCR reaction; Master Mix 1 Master Mix 2 (per reaction) Expand High Fidelity buffer (plus magnesium, 1.5mM final) (5μl) Expand High Fidelity polymerase: (0.6μl) Sterile water: (19.4μl) Added 25μl Master Mix 2 to Master mix 1 and overlaid with mineral oil. Both PCR fragments and pJONEX4 vector were subjected to a double restriction digest using Sacl/Hindlll and purified using the QIAquick clean up kits (Qiagen). The digested PCR fragment was then ligated to the above digested vector and transformed in to E. coli M72 (λ) cells by the method of electroporation. Plasmid mini preps were produced from positive transformants and screened by restriction digest using Sacl/Hindlll and by PCR using nucleotides TrcRBSsacl and TrcHindrev for Ghstop and TrcRBSsacl and GHRA835H for GHlinkGHR. Clones with the correct insert size were then sequenced using GHSl-23, GhseqF, Xpress forward and GHA573not. Cloning full length IL-6 and gp!30 into pTZ18U/pTrcHis-TOPO/pJONEX4 vectors The IL-6 / gpl30 chimeras are provided in a variety of vectors. Cloning into pTZ18U will facilitate in vitro mutagenisis and the pJONEX and pTrcHis-TOPO vectors can be used to generate recombinant protein in E. coli which can be purified using Nickel columns. Cloning is into pTrcHis using the TA cloning strategy devised for Ghstop/GHlinlcGHR. The chimeras are then subcloned into the pJonex and pTZ18U system using the restriction sites BamHl /Hindlll. This would maintain the upstream RBS and Hist6 tag in pJONEX and allow insertion into pTZ18U (they have the same multiple cloning site) for mutagenesis experiments. The strategy is to TA clone in IL-6 (full length: see sequence below: Figure 1) with the 3 'prime nucleotide containing a Not 1 site together with another restriction site: Sail (or Xhol). This Sail site will thus allow the cloning of the gpl30 gene in to the Sail /Hindlll sites (Hindlll being in 3 'end of the pTrcHis vector). The linlcer can then be inserted into the Notl /Sail sites. The construct once sequenced is subloned into the pJonex and pTZ18U vectors using BamHI/Hindlll. IL-6 and gp!30 are amplified by PCR from IMAGE clones or cDNA from human lymphocytes. The following primers will be used in TA cloning of the IL-6 sequence as represented in Figure 11 into pTrcHis. Primers for cloning IL-6 into pTrcHis Forward (5'nucleotide) PRIMER 1 5' gtacccccagg agaagattcc aaagatgtag 3' (31 mer with 15gc) Reverse primer (3 'nucleotide: Notl/Sall and Stop codons are shown in bold, sequence shown in italics and underlined is insert sequence to keep*sequence in frame and as an overhang for Notl/Sall digestion and incorporates the stop codons) PRIMER 2 5' tgagggctcttcggcaaatg g gcggccgc tgataa gtcgac 3' (20 mer with llgc) 5' cagctg aatagt cgccggcg g gtaaacggcttctcgggagt 3' 5' tcgac ttatca gcggccgc c catttgccgaagagccctca 3 '(reverse nucleotide) The next stage is to sub-clone the gpl30 full length extracellular domain (322- 2112bp; see Figure 12). Clone gpl30 into the Sall/Hindlll sites Primers for cloning full length gp!30 into pTrcHis-TOPO Forward primer (5'nucleotide : Sail site shown in bold) PRIMER 3 5' gggaaa gtcgac gaacttcta gatccatgtg gtt3' (22 mer 9gc) Reverse primer (Hindlll and stop codons shown in bold) PRIMER 4 5' ccaaa gtttgct caaggagaaattgaa tgataa aagctt gggaaa 3' 5' aaaggg ttcgaa aatagt aagttaaagaggaac tcgtttg aaacc3 ' 5' tttccc aagctt ttatca ttcaatttctccttg agcaaac tttgg3 ' (reverse nucleotide) The step 3 is to ligate in the linker duplex that contain a 5 'Notl site and a 3 'Sail site. LINKER DUPLEX G4S4 Not/Sail (5' overhang for Notl and 3'overhang for Sail are shown in bold) PRIMER 7 5 'ggccgcggtggcggaggtagtggtggcggaggtagcggtggcggaggttctggtggcggaggttcc g G4S4rev/ Not/Sal 1(5' overhang for Notl and Sail are shown in bold) PRIMER 8 5' tcgac ggaacctccgccaccagaacctccgccaccgctacctccgccaccactacctccgccacc gc 3' This produces a full length construct: IL-6/link/gpl30. The next step is to carry out cloning of domain deletions of gpl30 into the Sall/Hindlll sites. Primers for cloning gp!30 DI deletion in to pTrcHis-TOPO (Sall/ΗindlH sites) forward primer (Sail site shown in bold) PRIMER 5 5' gggaaa gtcgac atttcaggcttgcctcca 3 ' Reverse primer (Hindlll and stop codons shown in bold) PRIMER 4 5' ccaaa gtttgct caaggagaaattgaa tgataa aagctt gggaaa 3' 5' aaaggg ttcgaa aatagt aagttaaagaggaac tcgtttg aaacc3 ' 5' tttccc aagctt ttatca ttcaatttctccttg agcaaac tttgg3 ' (reverse nucleotide) The next step is to clone in gpl30 truncation up to 922bp (this deletes domains 1 and 2 from the extracellular region of gpl30). Construct IL-6/linlc/gpl30Dl Primers for cloning gp!30 (922-2112bp fragment) Forward primer (Sail site shown in bold) PRIMER 6 5' gggaaa gtcgac aatccgccacataatttat 3 ' Reverse primer (Hindlll and stop codons shown in bold) PRIMER 4 5' ccaaa gtttgct caaggagaaattgaa tgataa aagctt gggaaa 3' 5' aaaggg ttcgaa aatagt aagttaaagaggaac tcgtttg aaacc3 ' 5' tttccc aagctt ttatca ttcaatttctccttg agcaaac tttgg3 ' (reverse nucleotide) Preparation of Electrocompetant M72 (λ) cells M72 (λ) cells were grown o/n in 50ml LB. 100ml of this o/n culture was then added to 900ml LB and grown at 0°C until OD600 was between 0.5-0.6. Cells were then harvested at 4000rpm, 20 min at room temperature using a Sorval RC-3B centrifuge. The pellet was resuspended and re-centrifuged at 4000rpm, 4°C, 20 minutes in gradually reducing volumes of sterile ice cold 10%> (v/v) glycerol of 1000ml, 500ml, 250ml. The pellet was finally resuspended in lOOOμl of 10%> (v/v) glycerol, divided in to lOOμl aliquots. flash frozen in liquid nitrogen and stored at -80°C. Transformation of M72 cells. Electrocompetant M72 (λ) cells were defrosted on ice and placed in to an electroporation cuvette (cell width of 0.1cm, Invitrogen) and electroporated at 1.8KN. Positive tranformants were selected for on LB plates supplemented with lOOμg/ml ampicillin and grown at 30°C overnight. Induction of Expression of constructs from pTrcHis-TOPO vectors Transformed E. coli TOP 10 cells were grown overnight at 37 ° C with shaking at 200rpm in lOml LB supplemented with ampicillin (lOOμg/ml final). The next day 5ml of the overnight was used to seed 250ml LB supplemented with ampicillin (lOOμg/ml final) and grown to an OD600 = 0.6. The culture was then induced with the addition of IPTG to a final concentration of ImM and the cells grown for a further 5hrs. Induced cells were then harvested by centrifugation at 13000rpm, room temperature and the pellet either frozen or lysed. Induction of Expression of constructs from pJONEX vectors Transformed E. coli M72 (λ) cells were grown o/n at 30°C with shaking at 2000rpm in LB supplemented with ampicillin (lOOμg/ml). The next day the o/n culture was used to seed fresh LB and cells were grown until an OD600 of approximately 0.6 was reached. The temperature of the incubator was then adjusted to 42 °C and an equal volume of pre-warmed media was added to bring the temperature ofthe culture up to 42°C. The cells were then grown at 42°C for a further 4-51ιrs then harvested. Purification of induced proteins by immobilised metal affinity chromatography (IMAC) Induced cell pellets were resuspended in 20mM sodium phosphate buffer, 500mM sodium chloride, pH 7.8 and lysed by the addition of hen egg white lysozyme to a final concentration of lOOμg/ml, and left on ice for 15 minutes. The cells suspension was then sonicated by applying three 10 second bursts on a medium intensity setting whilst holding on ice. Insoluble material was then removed by centrifugation at 40000 x g, 4°C for 20 minutes in a RC-3B centrifuge. The cleared cell lysate was then applied to a Probond resin column (Invitrogen) pre- equilibrated with 20mM sodium phosphate buffer, 500mM NaCl, pH 7.8. The column washed with 20mM sodium phosphate buffer, 500mM sodium chloride, pH 7.8 buffer followed by washing with 20mM sodium phosphate buffer, 500mM sodium chloride, pH 6.0. Bound protein was eluted by an increasing gradient of 50mM to 500mM imidazole made up in 20mM sodium phosphate buffer, 500mM sodium chloride, pH 6.0 buffer. 1ml fractions were collected and purification monitored by bradford protein assay and SDS-PAGE. Fractions containing proteins of interest were pooled and dialysed against 1000 volumes 20mM sodium phosphate buffer, pH 7.8, for 2, 4 and 6 hours respectively. Dialysed protein was then concentrated (if needed) using an Amicon Centriprep Y-10 column. Dialysed and concentrated samples were then either stored at 4°C or frozen or used directly in a bioassay for growth hormone activity. Bioassay of rGH and purified growth hormone constructs Helc293 cells were previously stabily transfected with full-length human growth hormone receptor. Cells were routinely cultured in Dulbeccos MEM/Nutrient F12 medium supplemented with 10% Foetal calf serum, 1 % penicillin/streptomycin and 1%) L-glutamine. Cells used for the bioassay were first dissociated, counted, then plated at 2x105 cells/ml in growth medium in a 12 well plate and grown o/n at 37°C, 5% CO2. The next day cells were placed in rich medium [2/3 Dulbeccos MEM/F12 nutrient medium, 1/3 Dulbeccos 4.5g/L-glucose, 10% Foetal calf serum, 1%> penecillin/streptomycin and 1% L-glutamine] and incubated for 6 hours at 37°C. Transfection with reporter gene constructs was completed using the calcium phosphate transfection system (Life Technologies) according to the manufactures instructions. Cells were left overnight at 37°C, 5% C02. The next day cells were challenged with recombinant protein from 5-5000ng/ml, made up in " starvation medium [Dulbeccos MEM/Nutrient F12 medium supplemented with 1% penicillin/streptomycin, 1% L-glutamine] supplemented with lOOng/μl dexamethasone. Where necessary recombinant wild type GH was mixed with purified GHstop or Chimeric protein in a competition assay. Cells were incubated at 37°C, 5% CO2 for at least 5 hours before assaying for luciferase and β-galactosidase activity. Luciferase/ β-galactosidase assay The assays were performed according to the manufacturers instructions. Briefly media was aspirated from a 12 well plate and cells lysed with 150μl reporter lysis buffer for 20 minutes at room temperature. For the β-galactosidase assay 25μl of each lysate was added to duplicate wells of a 96 well plate and mixed with 75μl assay buffer. The plate was incubated at 37°C until a yellow coloration had developed at which point the plate was read at 420nm. For the luciferase assay, 50μl of the remaining lysate was added to a luminometer cuvette to which was then added 50μl of luciferase substrate. The sample was mixed by vortexing for 10 seconds and fluorescence measured at 15 and 60 second intervals. The final data was corrected for β-galactosidase expression by presenting results as a ratio of luciferase:β-galactosidase activity measured. Figure 17 shows data generated from a reporter gene assay using purified GH stop and GHlinkGHR. Western blotting Samples from purification's were routinely analysed for growth hormone expression by first separating samples by 12% (v/v) SDS-PAGE under either reducing or non- reducing conditions and transferring to PVDF membrane. The membrane was then blocked in 4%(w/v) milk protein in PBS, supplemented with 0.05% (v/v) Tween 20 (PBS-T). The membrane was then probed with anti-growth hormone (10A7, mouse IgGl) at 1/2000 dilution in 1% (w/v) milk protein in PBS-T. After brief washing the membrane was probed with Sheep anti mouse-HRP (Amersham) at 1/5000 dilution in l%(w/v) milk protein in PBS-T. After extensive washing with PBS-T, specific protein bands were visualised using ECL western blot detection reagents (Amersham). Figure 16 shows a western blot of induced proteins expressed either in the pTrcHis-TOPO of pJONEX vector systems. Radioimmunoassay for growth hormone The human growth hormone assay was performed using the NETRIA human growth hormone IRMA assay which uses a rabbit polyclonal and a labelled monoclonal antibody. Table 1: RIA results for induced lysates of Ghstop and GHlinkGHR Testing metabolic clearance rate in vivo Sprague-Dawley rats are anaesthetised and cannulae implanted in femoral and jugular veins. Two days later GH or chimera is administered by intravenous or subcutaneous injection. Blood samples are collected via the femoral cannula and chimera levels measured by radio-immunoassay (see table 2). Pharmacokinetic parameters are estimated using available computer programs fitting hormone concentration against time. Activation of GH signalling, measured as luciferase activity, by GH, negative control purification and Chi 1A2 (GH fused to GHR) A number of chimeric constructs were made. The partially purified chimera was prepared from transformed XL blue E. coli. Protein from untransformed XL blue E. coli was purified over nickel columns and used as a negative control to detect any non-specific agonist or antagonist action. All purified proteins were stored in glycerol. The negative control and Chimera 1A2 were incubated with and without GH. Figure 19 shows results of bioassay comparing the induction of a Stat5 reporter (luciferase activity) by growth hormone (GH), negative control (XL blue), and partially purified antagonist (Chimera 1 A2). The graph shows the expected dose-response to GH. Incubation with negative control showed no induction of luciferase activity but at high concentration partially inhibited the bioassay (this may be an effect ofthe increased glycerol concentration). At 500 ng/ml Chimera 1 A2 appeared to completely block GH signalling. References 1. Kishimoto, T., T. Taga, and S. Akira. 1994. Cytokine signal transduction. [Review] [92 refs]. Cell 76:253-262. 2. Muller-Newen, G., C. Kohne, and P.C. Heinrich. 1996. Soluble receptors for cytokines and growth factors. [Review] [58 refs]. International Archives of Allergy & Immunology 111 :99-ϊ 06. 3. Cunningham, B.C., M. Ultsch, A.M. de Vos, M.G. Mulkerrin, K.R. Clauser, and J.A. Wells. 1991. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 254:821-825. 4. de Vos, A.M., M. Ultsch, and A.A. Kossiakoff. 1992. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255:306-312. 5. Sundstrom, M., T. Lundqvist, J. Rodin, L.B. Giebel, D. Milligan, and G. Norstedt. 1996. Crystal structure of an antagonist mutant of human growth hormone, G120R, in complex with its receptor at 2.9 A resolution. Journal of Biological Chemistry 271:32197-32203. 6. Clackson, T., M.H. Ultsch, J.A. Wells, and A.M. de Vos. 1998. Structural and functional analysis ofthe 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. Journal of Molecular Biology 277:1111-1128. 7. Argetsinger, L.S. and C. Carter-Su. 1996. Growth hormone signalling mechanisms: involvement of the tyrosine lcinase JAK2. [Review] [19 refs]. Hormone Research 45 Suppl 1 :22-24. 8. Fuh, G., B.C. Cunningham, R. Fukunaga, S. Nagata, D.V. Goeddel, and J.A. Wells. 1992. Rational design of potent antagonists to the human growth hormone receptor. Science 256:1677-1680. 9. Ross, R.J., N. Esposito, X.Y. Shen, S. Von Laue, S.L. Chew, P.R. Dobson, M.C. Postel-Vinay, and J. Finidori. 1997. A short isoform ofthe human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein. Molecular Endocrinology 11 :265-273. 10. Chen, C, R. Brinkworth, and M.J. Waters. 1997. The role of receptor dimerization domain residues in growth hormone signalling. Journal of Biological Chemistry 272:5133-5140. 11. Chen, W.Y., D.C. Wight, T.E. Wagner, and J.J. Kopchick. 1990. Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proceedings of the National Academy of Sciences ofthe United States of America 87:5061-5065. 12. Chen, W.Y., D.C. Wight, BN. Mehta, T.E. Wagner, and J.J. Kopchick. 1991. Glycine 119 of bovine growth hormone is critical for growth-promoting activity. Molecular Endocrinology 5:1845-1852. 13. Chen, W.Y., M.E. White, T.E. Wagner, and J.J. Kopchick. 1991. Functional antagonism between endogenous mouse growth hormone (GH) and a GH analog results in dwarf transgenic mice. Endocrinology 129:1402- 1408. 14. Chen, W.Y., Ν.Y. Chen, J. Yun, T.E. Wagner, and J.J. Kopchick. 1994. In vitro and in vivo studies of antagonistic effects of human growth hormone analogs [published erratum appears in J Biol Chem 1994 Aug 12;269(32):20806]. Journal of Biological Chemistry 269:15892- 15897. 15. Mellado, M., J.M. Rodriguez-Frade, L. Kremer, C. von Kobbe, A.M. de Ana, I. Merida, and A. Martinez. 1997. Conformational changes required in the human growth hormone receptor for growth hormone signalling. Journal of Biological Chemistry 272:9189-9196. 16. Maamra, M., J. Finidori, S. Von Laue, S. Simon, S. Justice, J. Webster, Dower, and R. Ross. 1999. Studies with a growth hormone antagonist and dual- fluorescent confocal microscopy demonstrate that the full-length human growth hormone receptor, but not the truncated isoform, is very rapidly internalized independent of Jak2-Stat5 signalling. Journal of Biological Chemistry 274:14791-14798. 17. Cunningham, B.C., H.B. Lowman, J.A. Wells, R.G. Clark, K. Olson, and G. Fuh. 1998. Human growth hormone variants. US Patent #5 849:535 18. Thorner, M.O., C.J. . Strasburger, Z. Wu, M. Straume, M. Bidlingmaier, S. Pezzoli, K. Zib, J.C. Scarlett, and W.F. Bennett. 1999. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036- PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. Journal of Clinical Endocrinology & Metabolism 84:2098-2103. 19. Ayling, R.M., R. Ross, P. Towner, S. Von Laue, J. Finidori, S. Moutoussa y, CR. Buchanan, P.E. Clayton, and M.R. Norman. 1997. A dominant- negative mutation of the growth hormone receptor causes familial short stature [letter]. Nature Genetics 16:13-14. 20. Quinton, N.D., R.F. Smith, P.E. Clayton, M.S. Gill, S. Shalet, S.K. Justice, Simon, SA, S. Walters, M.C. Postel-Vinay, A.I.F. Blakemore, Ross, and RJM. 1999. Leptin binding activity changes with age: The link between leptin and puberty. Journal of Clinical Endocrinology & Metabolism 84:2336-2341. 21. Haffner, D., F. Schaefer, J. Girard, E. Ritz, and O. Mehls. 1994. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. Journal of Clinical Investigation 93:1163-1171. 22. Maini, R., E.W. St Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, Smolen, P. Emery, G. Harriman, M. Feldmann, and P. Lipsky. 1999. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932-1939. 23. Weinblatt, M.E., J.M. Kremer, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleischmann, Fox, RI, CG. Jackson, M. Lange, and DJ. Burge. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor :Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate [see comments]. New England Journal of Medicine 340:253-259. 24. Mohler, KM., P.R. Sleath, J.N. Fitzner, D.P. Cerretti, M. Alderson, S.S. Kerwar, D.S. Torrance, C. Otten-Evans, T. Greenstreet. and K. Weerawarna. 1994. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370:218-220. 25. Mohler, K.M., D.S. Torrance, CA. Smith, R.G. Goodwin, K.E. Stremler, V.P. Fung, H. Madani, and M.B. Widmer. 1993. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. Journal of Immunology 151:1548-1561. 26. Ghilardi, N., S. Ziegler, A. Wiestner, R. Stoffel, M.H. Heim, and R.C. Skoda. 1996. Defective STAT signalling by the leptin receptor in diabetic mice. Proceedings of the National Academy of Sciences ofthe United States of America 93:6231-6235. 27. Tartaglia, L.A. 1997. The leptin receptor. [Review] [59 refs]. Journal of Biological Chemistry 272:6093-6096. 28. Taitaglia LA, Dembski M, Weng X et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 1995; 83(7).T263-1271. 29. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 1999; 283(5404):987-990. 30. ' Remy I, Wilson IA, Michniclc SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 1999; 283(5404):990-993. 31. BAUMANN, G. (1991) Growth hormone heterogeneity: genes, isohormones. variants, and binding proteins. Endocrine Reviews, 12, 424-449. 32. HAFFNER, D., SCHAEFER, F., GIRARD, J., RITZ, E. & MEHLS, O. (1994) Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. Journal of Clinical Investigation, 93, 1163-1171. 33. JOHNSON, V. & MAACK, T. (1977) Renal extraction, filtratiom, absorption, and catabolism of growth hormone. American Journal of Physiology, 233, F185-F196 34. MANTZOROS, C.S. & FLIER, J.S. (2000) Editorial: leptin as a therapeutic agent - trials and tribulations. Journal of Clinical Endocrinology & Metabolism, 85, 4000-4002. 35. PEEL, CJ., BAUMAN, D.E., GOREWIT, R.C. & SNIFFEN, CJ. (1981) Effect of exogenous growth hormone on lactational performance in high yielding dairy cows. Journal of Nutrition, 111, 1662-1671. 36. SYED, S., SCHUYLER, P.D., KULCZYCKY, M. & SHEFFIELD, W.P. (1997) Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood, 89, 3243-3252.

Claims: CLAIMS 1. A binding agent comprising a first part capable of binding a ligand binding domain of a receptor linked to a second part comprising a receptor binding domain wherein said binding agent modulates the activity ofthe receptor. 2. A binding agent according to claim 1 wherein the binding agent antagonises the activity ofthe receptor. 3. A binding agent according to claim 1 wherein the binding agent agonises the activity ofthe receptor. 4. A binding agent according to any of claims 1 to 3 wherein the first part comprises a cytokine or the binding domain of a cytokine. 5. A binding agent according to claim 4 wherein the cytokine or the binding is selected from the following: growth hormone; leptin; erythropoietin; prolactin; TNF, interleukins (IL), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11; the p35 subunit of IL-12, IL-13, IL-15; granulocyte colony stimulating factor (G-CSF); granulocyte macrophage colony stimulating factor (GM-CSF); ciliary neurotrophic factor (CNTF); cardiotrophin-1 (CT-1); leukemia inhibitory factor (LIF); oncostatin M (OSM); interferon, IFNoc and IFNγ. 6. A binding agent according to claim 4 or claim 5 wherein the second part comprises at least part of the cognate receptor of the cytokine or a part of an associated receptor. 7. A binding agent according to claim 5 or claim 6 wherein the first part is GH. 8. A binding agent according to any of claims 4 to 7 wherein the second part is one extracellular domain of GHR. 9. A binding agent according to claim 8 wherein the second part is the C- terminal SD-100 domain of GHR. 10. A binding agent according to claim 5 or claim 6 wherein the first part is IL-6 or a binding domain of IL-6 and the second part is a part of the IL-6 receptor or gp 130. 11. A binding agent according to any of claims 1 to 10 wherein the binding agent is a fusion protein. 12. A binding agent according to any of claims 1 to 11 wherein the first part is linked by a linker to the second part. 13. A binding agent according to claim 12 wherein the first part is GH and linkage is made between a residue close to the C-terminus of the GFI molecule and a residue close to the N-terminus ofthe GHR. 14. A binding agent according to claim 13 wherein linkage is made between a residue close to the C-terminus of the GH molecule and a residue close to the N- terminal ofthe N-terminal ofthe C-terminal SD-100. 15. A binding agent according to claim 14 wherein linkage is made at any of residues 126-128 of the N-terminus ofthe C-terminal SD-100 ofthe GHR. 16. A binding agent according to claim 15 wherein linkage is made at residue 127 of the N-terminus ofthe C-terminal SD-100. 17. A binding agent according to any of claims 12 to 16 wherein the linker is a nucleic acid, a peptide nucleic acid or a chemical crosslinker. 18. A binding agent according to claim 17 wherein the linker is a peptide.. 19. A binding agent according to claim 18 wherein the linlcer is a polypeptide which comprises 5 to 30 amino acid residues. 20. A binding agent according to claim 19 wherein the linlcer comprises 10 to 20 amino acid residues. 21. A binding agent according to any of claims 18 to 20 wherein the linker comprises at least one copy ofthe peptide: Gly Gly Gly Gly Ser (hereinafter referred to as "Gly4Ser"). 22. A binding agent according to claim 21 wherein the linker comprises two copies ofthe Gly4Ser linlcer. 23. A binding agent according to claim 21 wherein the linlcer comprises three copies ofthe Gly4Ser linlcer. 24. A binding agent according to claim 21 wherein the linlcer comprises four copies ofthe Gly4Ser linker. 25. A nucleic acid molecule comprising a nucleic acid sequence which encodes a binding agent according to any of Claims 1 to 24 selected from the group consisting of: i) the group comprising Figures 4, 5, 8, 9 and 21 ii) * nucleic acids which hybridise to the sequences of (i) above and which have receptor antagonising activity; and iii) nucleic acid sequences which are degenerate as a result of the genetic code to the sequences defined in (i) and (ii) above. 26. A nucleic acid according to Claim 25 which hybridises under stringent hybridisation conditions to the sequences represented in Figs 4, 5, 8, 9, or 21. 27. A polypeptide encoded by the nucleic acid according to claim 25 or 26. 28. A polypeptide according to claim 27 which is modified by deletion, addition or substitution of at least one amino acid residue. 29. A vector comprising the DNA molecule of any of claims 25 to 26. 30. A vector according to claim 29 wherein the vector is adapted for recombinant expression. 31. A vector according to claim 29 or claim 30 wherein said vector is an expression vector adapted for prokaryotic gene expression. 32. A vector according to claim 29 or claim 30 wherein said vector is an expression vector adapted for eukaryotic gene expression. 33. A vector according to any of claims 29 to 32 wherein said vector is provided with and therefore said binding agent includes a secretion signal to facilitate purification of said binding agent. 34. A cell transformed/transfected with the nucleic acid according to any of claims 25 to 26 or the vector according to any of claims 29 to 33. 35. A cell according to claim 34, wherein the cell is a eukaryotic cell. 36. A cell according to claim 35 wherein said cell is selected from the group consisting of: fungal cell; insect cell; amphibian cell; plant cell or mammalian cell. 37. A cell according to claim 34 wherein said cell is a prokaryotic cell. 38. A cell according to claim 37 wherein said cell is Escherchia coli. 39. A pharmaceutical composition comprising the binding agent according to any of claims 1-24. 40. A pharmaceutical composition according to claim 39 wherein said composition further comprises a earner, excipient and/or a diluent. 41. The use of a binding agent according to any of claims 1-24 for the manufacture of a medicament for use in the treatment of acromegaly; gigantism; GH deficiency; Turners syndrome; renal failure; osteoporosis; diabetes mellitus; cancer; obesity; insulin resistance; hyperlipidaemia; hypertension; anaemia;autoimmune and infectious disease; inflammatory disorders including rheumatoid arthritis (IL-6 chimera) 42. A method to prepare a binding agent polypeptide according to any of the preceding claims comprising: i) growing a cell transformed/transfected with a nucleic acid according to any of claims 25 to 26 or the vector of any of claims 29 to 33 in conditions conducive to the manufacture of said polypeptide; and ii) purifying said polypeptide from said cell, or its growth environment. 43. A method of treating a human or animal subject comprising administering an effective amount of the agent according to any of claims 1-24 or the pharmaceutical composition of any of claims 39 or 40 to said subject. 44. A nucleic acid comprising the nucleic acid sequence represented in Figure 4. 45. A nucleic acid comprising the nucleic acid sequence represented in Figure 5. 46. A nucleic acid comprising the nucleic acid sequence represented in Figure 8. 47. A nucleic acid comprising the nucleic acid sequence represented in Figure 9. 48. A nucleic acid comprising the nucleic acid sequence represented in Figure 21. 49. A polypeptide comprising the amino acid sequence of any of claims 6, 11 13 or 22. 50. A method for the manufacture of a binding agent according to any of claims 1-24 which provides a binding agent which has reduced systemic clearance comprising linlcmg a ligand binding domain of a receptor to a receptor binding domain. 51. A method according to claim 50 wherein said binding agent is at least 701cDa. 52. A method according to claim 51 wherein said binding agent is between 70 and 801cDa. 53. A method according to claim 52 wherein said binding agent is greater than 80kDa.

Inventors: ARTYMIUK PETER, ROSS RICHARD, SAYERS JON, ARTYMIUK, PETER, ROSS, RICHARD, SAYERS, JON
Applicants: ARTYMIUK PETER, ASTERION LTD, ROSS RICHARD, SAYERS JON, ARTYMIUK, PETER, ASTERION LIMITED, ROSS, RICHARD, SAYERS, JON
Application year: 2001
Main classification: C12N15
IPC codes: A61K38, A61P3, A61P5, A61P7, A61P9, A61P13, A61P19, A61P29, A61P31, A61P35, A61P37, C07K14, C07K19, C12N1, C12N5, C12N15, C12P21